Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide and its prevalence increases with that of metabolic syndrome and its components. NAFLD is associated with complications such as cirrhosis and hepatocellular carcinoma. Diagnosis is mainly based on liver biopsy, but there are validated non-invasive methods. The purpose of the study was to assess the impact of metabolic steatopathy in patients with metabolic syndrome in Cameroon. Methods: This was a cross-sectional and analytical study conducted over a 6-month period from January 1st, 2019, to August 31st, 2022. Included were patients with metabolic syndrome who had consulted in endocrinology or gastroenterology at Yaoundé Central Hospital, Douala General Hospital and Douala Gyneco-obstetric and Pediatric Hospital. The diagnosis of NAFLD was made on abdominal ultrasound in front of a homogeneous or heterogeneous hyperechogenic aspect of the hepatic parenchyma compared to that of the right renal cortex called “brilliant liver” and fibrosis evaluated through non-invasive scores (Fib4 and NALFD Fibrosis score). Logistic regression by a uni- and multivariate analysis made it possible to search for the associated factors. Results. We included 133 patients. The female sex represented 64.7%. The mean age was 55 ± 9 years. The prevalence of NAFLD was 48.9%. At the evaluation of fibrosis was significant according to FIB-4 and NAFLD fibrosis score respectively in 6.2% and 4.6% of cases. The independently associated factors were Triglyceridemia ≤ 1.5 g/l (OR = 0.33; 95% CI [0.11 - 0.95]; p = 0.04) and LDL hypercholesterolemia (OR = 2.94; 95% CI [1.07 - 8.11]; p = 0.036). Conclusion: NAFLD was present in almost half of patients with metabolic syndrome. We had very few patients with significant fibrosis, but it needs to be further evaluated. The associated factors are hypertriglyceridemia and LDL hypercholesterolemia.
References
[1]
Burt, A.D., Lackner, C. and Tiniakos, D.G. (2015) Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Seminars in Liver Disease, 35, 207-220. https://doi.org/10.1055/s-0035-1562942
[2]
Chan, W.K. and Wong, V.W. (2022) Meaning of Non-Overlapping Patients between the MAFLD and NAFLD Definitions. Liver International, 42, 271-273. https://doi.org/10.1111/liv.15142
[3]
Serfaty, L. and Lemoine, M. (2008) Definition and Natural History of Metabolic Steatosis: Clinical Aspects of NAFLD, NASH and Cirrhosis. Diabetes & Metabolism, 34, 634-637. https://doi.org/10.1016/S1262-3636(08)74597-X
[4]
Duseja, A. and Chalasani, N. (2013) Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease (NAFLD). Hepatology International, 7, 755-764. https://doi.org/10.1007/s12072-013-9480-x
[5]
Bellentani, S. and Marino, M. (2009) Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease (NAFLD). Annals of Hepatology, 8, S4-S8. https://doi.org/10.1016/S1665-2681(19)31820-4
[6]
Riazi, K., Azhari, H., Charette, J.H., Underwood, F.E., King, J.A., Afshar, E.E., et al. (2022) The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 7, 851-861. https://doi.org/10.1016/S2468-1253(22)00165-0
[7]
Le, M.H., Yeo, Y.H., Li, X., Li, J., Zou, B., Wu, Y., et al. (2022) 2019 Global NAFLD Prevalence: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 20, 2809-2817. E28. https://doi.org/10.1016/j.cgh.2021.12.002
[8]
Golabi, P., Paik, J., Hwang, J.P., Wang, S., Lee, H.M. and Younossi, Z.M. (2019) Prevalence and Outcomes of Non-Alcoholic Fatty Liver Disease (NAFLD) among Asian American Adults in the United States. Liver International, 39, 748-757. https://doi.org/10.1111/liv.14038
[9]
Perumpail, B.J., Khan, M.A., Yoo, E.R., Cholankeril, G., Kim, D. and Ahmed, A. (2017) Clinical Epidemiology and Disease Burden of Nonalcoholic Fatty Liver Disease. World Journal of Gastroenterology, 23, 8263-8276. https://doi.org/10.3748/wjg.v23.i47.8263
[10]
Kim, D., Kim, W., Adejumo, A.C., Cholankeril, G., Tighe, S.P., Wong, R.J., et al. (2019) Race/Ethnicity-Based Temporal Changes in Prevalence of NAFLD-Related Advanced Fibrosis in the United States, 2005-2016. Hepatology International, 13, 205-213. https://doi.org/10.1007/s12072-018-09926-z
[11]
Nakatsuka, T., Tateishi, R. and Koike, K. (2022) Changing Clinical Management of NAFLD in Asia. Liver International, 42, 1955-1968. https://doi.org/10.1111/liv.15046
[12]
Nabi, O., Lacombe, K., Boursier, J., Mathurin, P., Zins, M. and Serfaty, L. (2020) Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: The French Nationwide NASH-CO Study. Gastroenterology, 159, 791-793.e2. https://doi.org/10.1053/j.gastro.2020.04.048
[13]
Younossi, Z., Anstee, Q.M., Marietti, M., Hardy, T., Henry, L., Eslam, M., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 15, 11-20. https://doi.org/10.1038/nrgastro.2017.109
[14]
Stéatose, M.L. (2020) Simple et stéatohépatite non alcoolique chez les patients camerounais diabétiques de type 2 nouvellement diagnostiqués à l’hopital central de Yaoundé. Thèse de doctorat., Université de Yaoundé I, Yaoundé.
[15]
Abodo, J.D.K., Danho, J., Léilatou, M., Koffi-Dago, P., Hué, A., Yao, A., Kouassi, F., N’Guessan, A. and Bathaix, F. (2022) Stéatopathie métabolique hépatique évaluée par le FibroScan® avec contrôle des paramètres d’atténuation (CAP) chez la personne diabétique de type 2 en Côte d’Ivoire. Médecine des Maladies Métaboliques, 16, 550-507. https://doi.org/10.1016/j.mmm.2022.04.004
[16]
Compaoré, N.I., Coulibaly, A., Koura, M., Somda, K.S., Somé, C.C., Zombré, N.M. S. and Bougouma, A. (2021) La stéatose hépatique métabolique liée à l'obésité chez l 'adulte Burkinabé. Pan African Medical Journal, 38, Article No. 266. https://doi.org/10.11604/pamj.2021.38.266.22253
[17]
Fresneda, S., Abbate, M., Busquets-Cortes, C., Lopez-Gonzalez, A., Fuster-Parra, P., Bennasar-Veny, M., et al. (2022) Sex and Age Differences in the Association of Fatty Liver Index-Defined Non-Alcoholic Fatty Liver Disease with Cardiometabolic Risk Factors: A Cross-Sectional Study. Biology of Sex Differences, 13, Article No. 64. https://doi.org/10.1186/s13293-022-00475-7
[18]
Trepo, E. and Valenti, L. (2020) Update on NAFLD Genetics: From New Variants to the Clinic. Journal of Hepatology, 72, 1196-1209. https://doi.org/10.1016/j.jhep.2020.02.020
[19]
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. https://doi.org/10.1002/hep.28431
[20]
Younossi, Z.M., Golabi, P., de Avila, L., Paik, J.M., Srishord, M., Fukui, N., et al. (2019) The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Hepatology, 71, 793-801. https://doi.org/10.1016/j.jhep.2019.06.021
[21]
Yun, H., Cheng, H.Y.W., Chang, W.H., Lin, S.C., Chu, C.H., Wang, T.E., Liu, C.C. and Shih, S.C. (2013) Nonalcoholic Fatty Liver Disease: Prevalence, Influence on Age and Sex, and Relationship with Metabolic Syndrome and Insulin Resistance. International Journal of Gerontology, 7, 194-198. https://doi.org/10.1016/j.ijge.2013.03.008
[22]
Garcia-Compean, D. and Jimenez-Rodriguez, A.R. (2022) NAFLD VS MAFLD. The Evidence-Based Debate Has Come. Time to change? Annals of Hepatology, 27, Article 100765. https://doi.org/10.1016/j.aohep.2022.100765
[23]
Pafili, K. and Roden, M. (2021) Non-Alcoholic Fatty Liver Disease (NAFLD) from Pathogenesis to Treatment Concepts in Humans. Molecular Metabolism, 50, Article 101122. https://doi.org/10.1016/j.molmet.2020.101122
[24]
Tourkochristou, E., Assimakopoulos, S.F., Thomopoulos, K., Marangos, M. and Triantos, C. (2022) NAFLD and HBV Interplay—Related Mechanisms Underlying Liver Disease Progression. Frontiers in Immunology, 13, Article 965548. https://doi.org/10.3389/fimmu.2022.965548
[25]
Guo, X., Yin, X., Liu, Z. and Wang, J. (2022) Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. International Journal of Molecular, 23, Article 15489. https://doi.org/10.3390/ijms232415489
[26]
Rohr, L., Lemmer, P., Henning, M., Tannapfel, A., Baars, T., Manka, P., et al. (2023) Patients with NAFLD Exhibit More Advanced Fibrosis in Liver Biopsy Than Patients with Other Chronic Liver Diseases. Zeitschrift für Gastroenterologie, 61, 29-36. https://doi.org/10.1055/a-1960-4006
[27]
Pais, R. and Maurel, T. (2021) Natural History of NAFLD. Journal of Clinical Medicine, 10, Article 1161. https://doi.org/10.3390/jcm10061161
[28]
European Association for the Study of the Liver, European Association for the Study of D and European Association for the Study of Obesity (2016) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 64, 1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
[29]
Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. (2012) The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 142, 1592-1609. https://doi.org/10.1053/j.gastro.2012.04.001
[30]
Bekolo Nga, W.T., Ndjitoyap Ndam, A.W., Kenfack, G., Nnang Olomo, A.L., Eloumou Bagnaka, S.A.F., Malongue, A., Tzeuton, C., Noah Noah, D., Namme, L.H., Njoya, O. and Ankouane Andoulo, F. (2020) évaluation de la Fibrose chez les Patients Porteurs d’une HépatiteVirale C Chronique et d’un Syndrome Métabolique: élastrométrie Impulsionnelle versus NAFLD Fibrosis Score. Health Sciences and Diseases, 21, 1-5.
[31]
Yessoufou, A.G., Behanzin, J., Djihoumeto, E., Isstina, Z.A., Ahokpe, M. and Sezan, A. (2015) Aspects épidémiologiques du syndrome métabolique au sein de la population obése de la Commune Ouidah au Sud-ouest du Bénin. Antropo, 33, 111-116.
[32]
Kaba, M.L., Sinayoko, M., Touré, A., Bah, A., Sylla, D., Diakité, F., Chérif, I., Bah, A.B., Bah, A.O. and Touré, Y.I. (2016) Profil épidémiologique et clinique des patients atteints de syndrome métabolique dans un service de médecine interne à Conakry. Néphrologie & Thérapeutique, 12, 408. https://doi.org/10.1016/j.nephro.2016.07.133
[33]
Houti, L., Hamani-Medjaoui, I., Lardjam-Hetraf, S.A., Ouhaibi-Djellouli, H., Goumidi, L. and Mediene-Benchekor, S. (2014) épidémiologie du syndrome métabolique dans la population urbaine en Algérie. Oran, Algérie. Revue d’ épidémiologie et de Santé Publique, 62, S226-S227. https://doi.org/10.1016/j.respe.2014.06.178
[34]
Ntagirabiri, R.C.J., Baransaka, E., Ndirahisha, E., Ndabaneze, E. and Niyongabo, T. (2014) Stéatose hépatique lors du syndrome métabolique chez l’adulte noir africain: Cas du Burundi. Journal Africain d’Hépato-Gastroentérologie, 8, 195-199. https://doi.org/10.1007/s12157-014-0553-9
[35]
Asabamaka, O.C., Ogbera, A.O. and Balogun, B.O. (2011) Non-Alcoholic Fatty Liver Disease and the Metabolic Syndrome in an Urban Hospital Serving African Community. Annals of Hepatology, 10, 119-124. https://doi.org/10.1016/S1665-2681(19)31559-5
[36]
Khammas, A.S.A., Hassan, H.A., Salih, S.Q.M., Kadir, H., Ibrahim, R.M., Nasir, N.N.M. and Mahmud, R. (2018) Prevalence and Risk Factors of Sonographically Detected non Alcoholic Fatty Liver Disease in a Screening Centre in Klang Valley, Malaysia: An Observational Cross-Sectional Study. Porto Biomedical Journal, 4, e31. https://doi.org/10.1016/j.pbj.0000000000000031
[37]
Yki-Järvinen, H. (2014) Non-Alcoholic Fatty Liver Disease as a Cause and a Consequence of Metabolic Syndrome. The Lancet Diabetes and Endocrinology, 2, 901-910. https://doi.org/10.1016/S2213-8587(14)70032-4
[38]
Cioffi, C.E., Welsh, J.A., Cleeton, R.L., Caltharp, S.A., Romero, R., Wulkan, M.L., et al. (2017) Natural History of NAFLD Diagnosed in Childhood: A Single-Center Study. Children, 4, Article 34. https://doi.org/10.3390/children4050034
[39]
Almobarak, A.O., Barakat, S., Suliman, E.A., Elmadhoun, W.M., Mohamed, N.A., Abobaker, I.O., et al. (2015) Prevalence of and Predictive Factors for Nonalcoholic Fatty Liver Disease in Sudanese Individuals with Type 2 Diabetes: Is Metabolic Syndrome the Culprit? Arab Journal of Gastroenterology, 16, 54-58. https://doi.org/10.1016/j.ajg.2015.06.001
[40]
Katsiki, N., Mikhailidis, P.D. and Mantzoros. C.S. (2016) Non-Alcoholic Fatty Liver Disease and Dyslipidemia: An Update. Metabolism, 65, 1109-1123. https://doi.org/10.1016/j.metabol.2016.05.003
